Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Pentabio Vaccine in Indonesian Infants
NCT01986322Phase 2Completed
- Sponsor
- Bio Farma
- Start
- Jul 2011
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Pentabio in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by Bio Farma. Primary endpoint: Protectivity of DTP/HB/Hib (Bio Farma) vaccine at 4 months. Started Jul 2011; status: completed.
02
Drugs
Pentabio
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01986322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01986322.